BioGaia AB (publ) (STO:BIOG.B)
Sweden · Delayed Price · Currency is SEK 113.00
-0.10 (-0.09%)
Aug 14, 2026, 5:29 PM CET
BioGaia AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,581 | 1,538 | 1,423 | 1,297 | 1,104 | 785.11 | |
Revenue Growth | 9.78% | 8.12% | 9.74% | 17.44% | 40.61% | 5.09% |
Cost of Revenue | 426.62 | 409.59 | 391.98 | 346.32 | 302.03 | 202.16 |
Gross Profit | 1,154 | 1,129 | 1,031 | 950.19 | 801.93 | 582.95 |
Selling, General & Admin | 599.7 | 560.89 | 464.28 | 402.51 | 360.62 | 230.76 |
Research & Development | 116.44 | 115.72 | 105.95 | 106.78 | 106.81 | 105.47 |
Other Operating Expenses | - | - | - | - | - | 0 |
Operating Expenses | 716.14 | 676.61 | 570.23 | 509.28 | 467.42 | 336.23 |
Operating Income | 437.86 | 451.97 | 460.51 | 440.91 | 334.51 | 246.72 |
Interest Expense | -4.91 | -6.06 | -1.44 | -0.81 | -5.39 | -1.13 |
Interest & Investment Income | 10.09 | 17.2 | 39.37 | 41.53 | 7.96 | 0.11 |
Currency Exchange Gain (Loss) | 2.31 | -39.56 | 13.89 | 1.82 | 26.79 | 11.14 |
Other Non Operating Income (Expenses) | -2.17 | -2.39 | -13.48 | - | 3.56 | - |
EBT Excluding Unusual Items | 443.18 | 421.16 | 498.85 | 483.45 | 367.44 | 256.84 |
Merger & Restructuring Charges | - | - | - | - | - | -4.23 |
Impairment of Goodwill | - | - | -5.3 | - | - | - |
Asset Writedown | - | - | -45.85 | - | - | - |
Other Unusual Items | 1.26 | 0.06 | 0.12 | -14.62 | 80.17 | 0.1 |
Pretax Income | 444.44 | 421.22 | 447.82 | 468.83 | 447.61 | 252.71 |
Income Tax Expense | 97.22 | 88.46 | 96.43 | 103.48 | 73.84 | 56.44 |
Earnings From Continuing Operations | 347.23 | 332.76 | 351.39 | 365.35 | 373.77 | 196.27 |
Net Income to Company | 347.23 | 332.76 | 351.39 | 365.35 | 373.77 | 196.27 |
Net Income | 347.23 | 332.76 | 351.39 | 365.35 | 373.77 | 196.27 |
Net Income to Common | 347.23 | 332.76 | 351.39 | 365.35 | 373.77 | 196.27 |
Net Income Growth | 21.14% | -5.30% | -3.82% | -2.25% | 90.44% | 9.20% |
Shares Outstanding (Basic) | 101 | 101 | 101 | 101 | 101 | 101 |
Shares Outstanding (Diluted) | 101 | 101 | 101 | 101 | 101 | 101 |
Shares Change | - | 0.09% | 0.09% | - | - | 13.11% |
EPS (Basic) | 3.43 | 3.29 | 3.48 | 3.62 | 3.70 | 1.94 |
EPS (Diluted) | 3.43 | 3.29 | 3.48 | 3.62 | 3.70 | 1.94 |
EPS Growth | 21.30% | -5.38% | -3.91% | -2.22% | 90.72% | -3.64% |
Free Cash Flow | 299.67 | 303.04 | 359.46 | 377.4 | 301.03 | 215.5 |
Free Cash Flow Per Share | 2.96 | 3.00 | 3.56 | 3.74 | 2.98 | 2.13 |
Dividend Per Share | 1.640 | 1.640 | 1.950 | 1.900 | 1.450 | 0.730 |
Dividend Growth | -15.90% | -15.90% | 2.63% | 31.03% | 98.63% | 7.04% |
Gross Margin | 73.01% | 73.37% | 72.45% | 73.29% | 72.64% | 74.25% |
Operating Margin | 27.70% | 29.38% | 32.37% | 34.01% | 30.30% | 31.42% |
Profit Margin | 21.97% | 21.63% | 24.70% | 28.18% | 33.86% | 25.00% |
Free Cash Flow Margin | 18.96% | 19.70% | 25.27% | 29.11% | 27.27% | 27.45% |
EBITDA | 454.58 | 468.92 | 477.17 | 455.44 | 348.71 | 259.98 |
EBITDA Margin | 28.76% | 30.48% | 33.54% | 35.13% | 31.59% | 33.11% |
D&A For EBITDA | 16.72 | 16.94 | 16.66 | 14.53 | 14.2 | 13.25 |
EBIT | 437.86 | 451.97 | 460.51 | 440.91 | 334.51 | 246.72 |
EBIT Margin | 27.70% | 29.38% | 32.37% | 34.01% | 30.30% | 31.42% |
Effective Tax Rate | 21.87% | 21.00% | 21.53% | 22.07% | 16.50% | 22.33% |